| Members |
targetComponentId |
| Thrombotic microangiopathy NOS |
Thrombotic microangiopathy (disorder) |
| Thrombus due to any device, implant AND/OR graft |
Thrombosis (disorder) |
| Thumb pulp flap |
Flap (substance) |
| Thymoma - category |
Thymoma |
| Thymoma, no International Classification of Diseases for Oncology subtype |
Thymoma of uncertain behaviour |
| Thymoma, type A |
Thymoma, type A, malignant |
| Thymoma, type AB |
Thymoma, type AB, malignant |
| Thymoma, type B1 |
Thymoma, type B1, malignant |
| Thymoma, type B2 |
Thymoma, type B2, malignant |
| Thymoma, type B3 |
Thymoma, type B3, malignant |
| Thymosin alpha 1 1.6mg powder for conventional release solution for injection vial |
Product containing only thymalfasin (medicinal product) |
| Thymosin alpha 1 1.6mg powder for injection solution vial + diluent |
Product containing only thymalfasin (medicinal product) |
| Thymoxamine 0.5% conventional release eye drops |
Product containing only moxisylyte in ocular dose form (medicinal product form) |
| Thymoxamine 0.5% preservative-free eye drops |
Product containing only moxisylyte in ocular dose form (medicinal product form) |
| Thyroid TNM finding |
American Joint Committee on Cancer allowable value |
| Thyroid eye disease with exophthalmos |
Exophthalmos due to thyroid eye disease (disorder) |
| Thyroid eye disease with strabismus |
Exophthalmos due to thyroid eye disease (disorder) |
| Thyroid gland excision |
Thyroidectomy |
| Thyroid related antibody |
Thyroid antibody |
| Thyrotropin alfa 0.9mg/mL powder for injection solution vial |
Thyrotrophin only product |
| Thyrotropin alfa 1.1mg/vial powder |
Thyrotrophin only product |
| Thyroxine sodium 100micrograms tablet |
Levothyroxine sodium anhydrous 100 microgram oral tablet |
| Thyroxine sodium 25micrograms tablet |
Product containing precisely levothyroxine sodium anhydrous 25 microgram/1 each conventional release oral tablet (clinical drug) |
| Thyroxine sodium 50micrograms tablet |
Levothyroxine sodium anhydrous 50 microgram oral tablet |
| Ticarcillin 3g/clavulanic acid 100mg powder for injection solution vial |
Product containing precisely clavulanic acid (as clavulanate potassium) 100 milligram and ticarcillin (as ticarcillin disodium) 3 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Ticarcillin disodium 1g powder for injection solution vial |
Product containing precisely ticarcillin (as ticarcillin disodium) 1 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Ticarcillin disodium 20g powder for injection solution vial |
Product containing precisely ticarcillin (as ticarcillin disodium) 20 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Ticarcillin disodium 3g powder for injection solution vial |
Product containing precisely ticarcillin (as ticarcillin disodium) 3 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Tiludronate disodium |
Product containing tiludronic acid (medicinal product) |
| Time zone syndrome |
Jet lag (finding) |
| Timed unsupported steady stand test |
Timed unsupported steady stand time |
| Timolol maleate 0.25% ophthalmic solution |
Timolol (as timolol maleate) 2.5 mg/mL eye drops |
| Timolol maleate 0.5% |
Product containing precisely timolol (as timolol maleate) 5 milligram/1 milliliter conventional release eye drops (clinical drug) |
| Timolol maleate 0.5% ophthalmic solution |
Product containing precisely timolol (as timolol maleate) 5 milligram/1 milliliter conventional release eye drops (clinical drug) |
| Timolol maleate+bendroflumethiazide |
Product containing bendroflumethiazide and timolol (medicinal product) |
| Tiotropium 18microgram inhalation powder capsule |
Tiotropium (as tiotropium bromide) 18 microgram/actuation powder for inhalation |
| Tiotropium 18microgram inhalation powder capsule with device |
Tiotropium (as tiotropium bromide) 18 microgram/actuation powder for inhalation |
| Tis (0): Carcinoma in situ (limited to fallopian tube mucosa) |
cTis |
| Tis (0): Carcinoma in situ (vagina) |
cTis |
| Tis category |
cTis |
| Tis: Carcinoma in situ ("flat tumor" of urinary bladder) |
cTis |
| Tis: Carcinoma in situ (endometrium/uterine cervix) |
cTis |
| Tis: Carcinoma in situ |
cTis |
| Tis: Epithelium only (carcinoma in situ, no invasion) |
cTis |
| Tis: Intratubular germ cell neoplasia (carcinoma in situ, testis) |
cTis |
| Tis: Tumor invades lamina propria (gastrointestinal tumor) |
American Joint Committee on Cancer cTis(LAMN) (qualifier value) |
| Tis: Tumor invades muscularis mucosae (colon/rectum) |
cTis |
| Tissue culture for chromosome analysis, more complex procedure with special extra counts |
Chromosome analysis |
| Tissue kallikrein |
Kininogen |
| Tissue processing technique, complex, embed, cut and stain, per autopsy |
Tissue processing technique |
| Tissue processing technique, complex, embed, cut and stain, per surgical specimen |
Tissue processing technique |
| Titanium dioxide 20% paste |
Product containing only titanium dioxide (medicinal product) |
| Tobacco dependence with current use |
Tobacco dependence syndrome |
| Tobramycin 0.3%/fluorometholone 0.1% ophthalmic suspension |
Product containing precisely fluorometholone acetate 1 milligram/1 milliliter and tobramycin 3 milligram/1 milliliter conventional release eye suspension (clinical drug) |
| Tobramycin 1.2g powder for injection solution vial |
Tobramycin (as tobramycin sulfate) 1.2 g powder for solution for injection vial |
| Tobramycin 1.2mg/mL injection |
Tobramycin (as tobramycin sulfate) 1.2 g powder for solution for injection vial |
| Tobramycin 300mg/5mL nebulizer solution |
Product containing precisely tobramycin 60 milligram/1 milliliter conventional release solution for nebulizer (clinical drug) |
| Tobramycin 60mg/mL solution |
Product containing precisely tobramycin 60 milligram/1 milliliter conventional release solution for nebulizer (clinical drug) |
| Tocilizumab 20mg/mL conventional release solution for injection |
Tocilizumab only product in parenteral dose form |
| Tocilizumab 20mg/mL solution for intravenous infusion |
Tocilizumab only product in parenteral dose form |
| Tocopherol |
Vitamin E and/or vitamin E derivative (substance) |
| Toe flap |
Flap (substance) |
| Tolnaftate+chlorhexidine hydrochloride |
Product containing chlorhexidine and tolnaftate (medicinal product) |
| Tolterodine 4mg m/r capsule |
Product containing only tolterodine in oral dose form (medicinal product form) |
| Tolterodine L-tartrate 4mg m/r capsule |
Product containing only tolterodine in oral dose form (medicinal product form) |
| Tolterodine L-tartrate 4mg m/r capsule |
Product containing only tolterodine in oral dose form (medicinal product form) |
| Tolterodine L-tartrate 4mg prolonged-release oral capsule |
Product containing only tolterodine in oral dose form (medicinal product form) |
| Tolterodine tartrate 2mg m/r capsule |
Product containing only tolterodine in oral dose form (medicinal product form) |
| Tolterodine tartrate 2mg prolonged-release oral capsule |
Product containing only tolterodine in oral dose form (medicinal product form) |
| Tolterodine tartrate 4mg m/r capsule |
Product containing only tolterodine in oral dose form (medicinal product form) |
| Toluene diisocyanate specific extract |
Toluene-2-4-diisocyanate |
| Tomato - dietary |
Tomato (substance) |
| Tomilol |
Timolol (substance) |
| Tomography - NOS |
Tomographic imaging procedure (procedure) |
| Tomography - NOS |
Tomographic imaging procedure (procedure) |
| Tongue flap |
Flap (substance) |
| Tonsil (& peritonsillar region) |
Palatine tonsillar structure |
| Tooth attrition |
Excessive attrition of teeth |
| Tooth decalcification |
Incipient enamel caries |
| Topical compound dexamethasone preparation allergy |
Allergy to dexamethasone |
| Topical compound hydrocortisone preparation allergy |
Allergy to hydrocortisone (finding) |
| Topical corticosteroid, group I |
Glucocorticoid (substance) |
| Topical corticosteroid, group II |
Glucocorticoid (substance) |
| Topical corticosteroid, group III |
Glucocorticoid (substance) |
| Topical corticosteroid, group IV |
Glucocorticoid (substance) |
| Topical corticosteroid, group V |
Glucocorticoid (substance) |
| Topical corticosteroid, group VI |
Glucocorticoid (substance) |
| Topical dermatological preparation adverse reaction |
Adverse reaction to drug |
| Topical dexamethasone allergy |
Allergy to dexamethasone |
| Topical estradiol allergy |
Allergy to estradiol (finding) |
| Topical hydrocortisone allergy |
Allergy to hydrocortisone (finding) |
| Topical prednisolone allergy |
Allergy to prednisolone |
| Topical salicylic acid allergy |
Allergy to salicylic acid (finding) |
| Topical selenium |
Selenium |
| Topical sulfur |
Sulfur |
| Topotecan 1mg powder for infusion solution vial |
Topotecan (as topotecan hydrochloride) 1 mg powder for solution for injection vial |
| Torday's elephant shrew |
Family Macroscelididae |
| Torek operation for orchiopexy |
Orchidopexy |
| Torsemide 10mg/mL injection solution ampule |
Product containing only torasemide in parenteral dose form (medicinal product form) |
| Torulopsis |
Candida |
| Torulopsis candida |
Candida saitoana |
FHIR